-
In-depth organoid profiling of pancreatic cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-09 Ju Eun Maeng, Ja-Lok Ku
In this Journal Club, Maeng and Ku discuss a study demonstrating that profiling drug responses in patient-derived organoids can identify responders to various therapies.
-
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-09 Amir Z. Munir, Alan Gutierrez, Juan Qin, Andrew H. Lichtman, Javid J. Moslehi
-
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-08 Roel Polak, Elisa T. Zhang, Calvin J. Kuo
-
ASS1: Guardian of the genome Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-05 Gabrielle Brewer
Lim et al. show that ASS1, silenced in many cancer types, is a metabolic checkpoint that, following DNA damage, halts cell cycle progression by restricting nucleotide synthesis and p53-related gene transcription.
-
Towards targeting the breast cancer immune microenvironment Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-05 Michael A. Harris, Peter Savas, Balaji Virassamy, Megan M. R. O’Malley, Jasmine Kay, Scott N. Mueller, Laura K. Mackay, Roberto Salgado, Sherene Loi
-
Carcinogenesis at single-cell resolution Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-04 Daniela Senft
In this study, Allan Balmain and colleagues used a mouse model to monitor stem cell networks at single-cell resolution during skin carcinogenesis, revealing two cancer stem cell states, rapid cycling and plasticity, between which cells can transition to drive tumour initiation, progression and therapy resistance.
-
Preprints as tools to advance careers Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-02 Samantha Hindle, Richard Sever
-
Oncologists must act to manage cancer detected through prenatal screening Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-07-01 Amy E. Turriff, Diana W. Bianchi
-
The rhythm of the night Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-25 Gabrielle Brewer
Patient progression and response to immunotherapy are directly influenced by the presence and quality of tumour-infiltrating leukocytes (TILs). In a recent Cell publication, Wang, Zeng et al. demonstrate the functional role of circadian rhythms in altering TIL functionality and quantity, highlighting the therapeutic potential of leveraging this understanding.
-
The road less travelled Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-21
In our Roadmap articles, we ask authors to provide a sense of direction to a field, to encourage new lines of thinking and experimentation, as well as opportunities for collaboration. This month, Nature Reviews Cancer launches Roadmap articles, in which we ask authors to provide a sense of direction to a field to encourage new lines of thinking and experimentation, as well as opportunities for collaboration
-
Why do patients with cancer die? Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-19 Adrienne Boire, Katy Burke, Thomas R. Cox, Theresa Guise, Mariam Jamal-Hanjani, Tobias Janowitz, Rosandra Kaplan, Rebecca Lee, Charles Swanton, Matthew G. Vander Heiden, Erik Sahai
-
Exploiting temporal aspects of cancer immunotherapy Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-17 Rachael M. Zemek, Valsamo Anagnostou, Inês Pires da Silva, Georgina V. Long, Willem Joost Lesterhuis
-
The importance of 3D fibre architecture in cancer and implications for biomaterial model design Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-17 J. C. Ashworth, T. R. Cox
-
The path to leptomeningeal metastasis Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-13 Jan Remsik, Adrienne Boire
-
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-12 Ashley M. Holder, Aikaterini Dedeilia, Kailan Sierra-Davidson, Sonia Cohen, David Liu, Aparna Parikh, Genevieve M. Boland
-
Charting spatially resolved cell states with CytoSPACE Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-10 Erin L. Brown
In this Tools of the Trade article, Erin Brown describes the development of CytoSPACE, a computational tool that aligns single-cell transcriptomes and spatial transcriptomic data, and highlights its use in identifying spatially resolved cell states in the tumour microenvironment.
-
Eliminating false positives Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-10 Daniela Senft
To establish microbiome-based screening for colorectal cancer, a study published in Nature Medicine tackled two key challenges: utilizing quantitative microbiome profiling and identifying covariates that might obscure the microbiota–colorectal cancer interactions.
-
Bone voyage: immune crosstalk sets sail Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-06-04 Gabrielle Brewer
Monteran et al. identified key interactions between granulocytes and T cells that promote an immunosuppressive bone microenvironment, enabling breast cancer metastasis.
-
No mutation, tumour initiation Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-29 Daniela Senft
Parreno et al. provide evidence for epigenetically initiated cancers in Drosophila and show that cancer develops after transient loss of Polycomb group proteins in the absence of recurrent mutations.
-
Liquid biopsies for Hodgkin lymphoma Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-23 Sojung Lim, Yoon Kyung Jeon
In this Journal Club, Lim and Jeon discuss a recent study demonstrating the utility of noninvasive genomic profiling for subtyping Hodgkin lymphomas.
-
Taking a detour Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-16 Anna Dart
Kong et al. have now shown that Knudson’s two-hit hypothesis can be circumvented through the actions of the glycolytic metabolite methylglyoxal, which transiently inactivates the tumour-suppressive functions of BRCA2 leading to episodic mutagenesis and cancer genome evolution.
-
Finding the truth in science Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-16 Elisabeth M. Bik
In a ‘publish or perish’ culture, some scientists may resort to questionable research practices or even fraud. Scientific paper mills and artificial intelligence increasingly threaten the pursuit of truth in science. Structural changes, including heightened scrutiny of papers and authorship and better funding, are needed to ensure scientific integrity.
-
A guide to artificial intelligence for cancer researchers Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-16 Raquel Perez-Lopez, Narmin Ghaffari Laleh, Faisal Mahmood, Jakob Nikolas Kather
-
Cancer therapy with antibodies Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-13 Suman Paul, Maximilian F. Konig, Drew M. Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Katharine M. Wright, Sandra B. Gabelli, Mitchell Ho, Andrea van Elsas, Shibin Zhou
-
Right ON target: a new RAS-GTP inhibitor Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-10 Daniela Senft
Two studies published concurrently in Nature report the development and preclinical activity of RMC-7977, a multi-selective inhibitor targeting the active, GTP-bound form of RAS.
-
AACR 2024 Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-08 Gabrielle Brewer
The annual American Association for Cancer Research (AACR) meeting provides a platform for scientists, clinicians and other stakeholders to share the latest advances in cancer science and medicine. Here, we outline some highlights of the 2024 meeting.
-
A MEGA RNA-editing tool Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-07 Victor Tieu
In this Tools of the Trade article, Victor Tieu describes the development of MEGA, a platform that exploits the RNA-targeting capability of CRISPR–Cas13d and demonstrates its use to improve the anti-tumour activity of CAR T cells.
-
Histological transformation to small-cell carcinoma Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-02 Songji Oh, Tae Min Kim
In this Journal Club, Oh and Kim discuss a study demonstrating the mechanisms underlying histological transformation of lung adenocarcinoma to neuroendocrine small-cell lung cancer.
-
Developmental origins shape the paediatric cancer genome Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-05-02 Xiaolong Chen, Wentao Yang, Charles W. M. Roberts, Jinghui Zhang
-
Too much of a good thing Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-30 Anna Dart
Dias et al. have shown that intentional further activation of oncogenic signalling rather than its inhibition represents an alternative strategy leading to colorectal cancer cell death with tumour suppressive acquired resistance.
-
Using the tumour microenvironment to improve therapy efficacy Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-26 Zuzana Tatarova
Targeted anticancer agents and chemotherapies exploit vulnerabilities intrinsic to cancer cells. However, evidence suggests the local tumour microenvironment (TME) can affect tumour behaviour to enhance or inhibit tumour growth. Drugs that target tumour cell vulnerabilities have been shown to also affect the TME. Understanding these effects will enable the development of drug combinations that directly
-
Investigating immune cells across time in vivo Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-22 Daniel Kirschenbaum
In this Tools of the Trade article, Daniel Kirschenbaum describes the development of Zman-seq and its utility for capturing dynamic changes in cellular state within single-cell RNA sequencing data.
-
Guardrails for the use of generalist AI in cancer care Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-16 Stephen Gilbert, Jakob Nikolas Kather
-
Combinatorial strategies to target RAS-driven cancers Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-16 Naiara Perurena, Lisa Situ, Karen Cichowski
-
Programming immune escape Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-12 Daniela Senft
In a recent study published in Nature, Goto et al. explore mechanisms of immune evasion in early colorectal cancers and adenomas and identify SOX17 to be crucial for immune escape through suppression of interferon-γ signalling.
-
NET-working under stress Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-12 Gabrielle Brewer
In this recent study, He et al. establish that chronic stress promotes metastasis through stress-induced formation of neutrophil extracellular traps (NETs).
-
Lymphatic vessels in the age of cancer immunotherapy Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-11 Triantafyllia Karakousi, Tenny Mudianto, Amanda W. Lund
-
Routes to second cancers Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-09 Anna Dart
Sánchez-Guixé et al. investigated the possible routes to second malignancies in survivors of paediatric cancer by studying four such clinical cases.
-
Revealing genomic secrets of archival FFPE samples Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-08 Kaile Wang
In this Tools of the Trade article, Kaile Wang describes the development and use of Arc-well, a high-throughput single-cell DNA sequencing method tailored to analyse archival formalin-fixed paraffin-embedded (FFPE) materials.
-
Global post-mortem tissue donation programmes to accelerate cancer research Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-08 Christine Desmedt, Lisa A Carey
-
Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-04-08 Tong Xiao, Juyeun Lee, Timothy D. Gauntner, Maria Velegraki, Justin D. Lathia, Zihai Li
-
Trastuzumab: dreams, desperation and hope Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-03-15 H. Michael Shepard
The story of trastuzumab begins with Axel Ullrich’s dedication to the concept that receptor tyrosine kinases must be the key to many human diseases. It continued with H. Michael Shepard’s dedication to making a cancer therapy that attacks tumour cells, not normal cells, and Dennis Slamon’s drive to save the lives of people with breast cancer. In this World View, H. Michael Shepard describes his personal
-
New pathogen on the block Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-03-11 Anna Dart
Fu et al. provide data indicating a pathogenic role for Streptococcus anginosus in gastric cancer.
-
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-03-07 Pascal Meier, Arnaud J. Legrand, Dieter Adam, John Silke
-
Catastrophic conformity Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-03-01 Gabrielle Brewer
Recently published in Nature, Fan et al. demonstrate that accumulation of advanced glycation end-products in the extracellular matrix of the liver increases viscoelasticity to promote hepatocellular carcinoma growth, independent of stiffness.
-
B-ring sterols to the rescue Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-03-01 Daniela Senft
Two independent studies published in Nature implicate distal cholesterol biosynthesis in the regulation of ferroptosis and show that 7-dehydrocholesterol (7-DHC) is an endogenous, anti-ferroptotic metabolite.
-
Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-02-29 Edward W. Tate, Lior Soday, Ana Losada de la Lastra, Mei Wang, Hening Lin
-
Extrachromosomal DNA in cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-02-26 Xiaowei Yan, Paul Mischel, Howard Chang
-
Black voices in cancer research and oncology Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-02-19 Kilan C. Ashad-Bishop, Onyinye D. Balogun, Runcie C. W. Chidebe, Leah M. Cook, Christina Towers
Over the past few years, there has been an increasing realization that we need a more equal, diverse and inclusive culture for truly successful cancer research to happen. Moreover, that research itself must be relevant to and engage a diverse patient population to achieve effective cancer care. Now is the time for action, so how do we attract and retain more diverse researchers to the cancer community
-
Fungi in cancer Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-02-12 Jessica Galloway-Peña, Iliyan D. Iliev, Florencia McAllister
Both the gut and the tumour microbiome are now established as crucial regulators of cancer phenotypes and have been implicated in cancer initiation, progression and therapy response. Although the role of bacteria in these processes is beginning to be unravelled, the relevance of fungi is only just emerging. In this Viewpoint, we asked experts to discuss the current knowledge on the mycobiome–cancer
-
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-02-12 Shaopeng Yuan, Jorge Almagro, Elaine Fuchs
-
Discovering new drivers of cancer aneuploidy Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-02-09 Juliann Shih
In this Tools of the Trade, Juliann Shih describes the development of BISCUT, which detects genomic loci that are subject to fitness advantages or disadvantages by interrogating the length distributions of partial somatic copy-number alterations to enable the discovery of new drivers of aneuploidy in cancer.
-
Cancer burden in low-income and middle-income countries Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-02-08 Sharmila Anandasabapathy, Chite Asirwa, Surbhi Grover, Chemtai Mungo
As cancer detection rates and therapy successes increase in high-income countries, it is predicted that over the next decade more than 75% of cancer-related deaths will occur in low-income and middle-income countries. Sub-Saharan Africa, which contains many of these countries, is currently unprepared with inadequate screening and detection methods, treatment and palliative care capacity. In this Viewpoint
-
Nanoreceptors take down mutant p53 Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-02-06 Gabrielle Brewer
Mutant gain-of-function p53 is commonly found in human cancers. Huang, Cao, Qian et al. developed and validated the use of multifunctional biomimetic nanoreceptors that bind to and promote the degradation of mutant p53 as a cancer therapy.
-
Inferring cancer metabolism from gene-expression data Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-02-05 Vakul Mohanty
In this Tools of the Trade article, Vakul Mohanty describes the development and use of METAFlux, a computational framework that infers metabolic flux from bulk and single-cell RNA-sequencing data.
-
Multiplex protein imaging in tumour biology Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-02-05 Natalie de Souza, Shan Zhao, Bernd Bodenmiller
-
Finding the needle in the haystack Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-02-02 Daniela Senft
Goddard et al. report that disseminated tumour cells evade T cell immunity due to their relative scarcity, which decreases the likelihood of T cell–tumour cell interactions.
-
Cholesterol-fuelled glioblastoma Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-01-31 Gabrielle Brewer
Zhao et al. identified lymphatic endothelial-like cells in glioblastoma and demonstrated their role in promoting tumour growth through increased glioblastoma cholesterol metabolism.
-
Differentiating high-grade neuroendocrine neoplasms Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-01-30 Rodrigo Gomes Taboada, Rachel P. Riechelmann
In this Journal Club, Taboada and Riechelmann discuss the importance of a study outlining a novel neuroendocrine neoplasm classification system.
-
Translating p53-based therapies for cancer into the clinic Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-01-29 Sylvain Peuget, Xiaolei Zhou, Galina Selivanova